Sterna biologicals GmbH & Co. KG is an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, and ulcerative colitis. By targeting transcription factors that play a central role in regulating Th1- and Th2-driven inflammatory mechanisms, the Company’s proprietary DNAzyme-based drug candidates can intervene with upstream inflammatory processes to address related diseases more effectively. Sterna currently has four programs in phase 2 development.
Phase l or ll
Anti-inflammatory, Immunotherapy, Respiratory
Marburg, Hessen 35037
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.